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W
e thank Stephens et al. (1) for
their comments in response to
the Structured Testing Program
(STeP) study. It is evident that we share
an interest in ensuring that health care
resources are used effectively, and we
therefore welcome the opportunity to ad-
dress the issues you have raised.
As noted in the letter, a number of
studies in noninsulin-treated diabetes have
shown data similar to those of Stephens
et al.—suggesting that self-monitoring
of blood glucose (SMBG), as it is typically
done, offers little or no glycemic beneﬁt
(2,3).Wedonotdisagree.Ourstudyprem-
ise,however, isthat SMBG ismerely atool,
and its usefulness is dependent on how it
is used. In standard usage, we recognize
that noninsulin-using patients and/or
their health care providers often do not
make use of SMBG data; indeed, they
may not know how to do so. If patients
do not test frequently enough and in a
structured manner to generate “action-
able” patterns of SMBG, and if such data
are not used to guide treatment changes,
we should not be surprised to see that
SMBG use is unrelated to glycemic status
(or glycemic improvement).
As we reported, SMBG is of value in
managing type 2 diabetes when the testing
regimen is structured, the results are
presented in a manner that yields easily
discernable blood glucose patterns,
and,perhapsmostimportantly,bothpa-
tients and health care providers use the
data to make appropriate therapeutic
changes (4).
Although the studies referenced by
Stephens et al.have received considerable
attention, particularly from health care
payers, it is important to recognize that
several other studies, in addition to our
own, have shown a beneﬁtt oS M B Gu s ei n
noninsulin-treated diabetes (4–6). Similar
to our study, these trials used structured
SMBG as an integral component of com-
prehensive interventions that included
systematic analysis, interpretation, and
use of SMBG data by both patients and
health care providers.
Insum, webelievethat itisunreason-
able to expect a positive relationship
between SMBG and glycemic control if
the blood glucose data are not used to
guide therapy. Thus, studies that simply
look at the frequency of test strip utiliza-
tion do not really assess the value of
appropriate SMBG use.
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